Zhejiang Starry Pharm Co Ltd - Asset Resilience Ratio
Zhejiang Starry Pharm Co Ltd (603520) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Zhejiang Starry Pharm Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Zhejiang Starry Pharm Co Ltd's Asset Resilience Ratio has changed over time. See net assets of Zhejiang Starry Pharm Co Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Starry Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603520 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥23.15K | 0.0% |
| Total Liquid Assets | CN¥23.15K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Starry Pharm Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Starry Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Starry Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Zhejiang Starry Pharm Co Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Starry Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CN¥23.15K ≈ $3.39K |
CN¥5.52 Billion ≈ $807.23 Million |
-0.02pp |
| 2022-12-31 | 0.02% | CN¥876.69K ≈ $128.29K |
CN¥5.30 Billion ≈ $775.88 Million |
-1.42pp |
| 2021-12-31 | 1.43% | CN¥70.16 Million ≈ $10.27 Million |
CN¥4.90 Billion ≈ $716.35 Million |
-1.53pp |
| 2020-12-31 | 2.97% | CN¥130.76 Million ≈ $19.13 Million |
CN¥4.41 Billion ≈ $644.79 Million |
+2.47pp |
| 2017-12-31 | 0.50% | CN¥10.00 Million ≈ $1.46 Million |
CN¥2.01 Billion ≈ $294.62 Million |
-3.20pp |
| 2016-12-31 | 3.70% | CN¥70.00 Million ≈ $10.24 Million |
CN¥1.89 Billion ≈ $277.08 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more